1 completed. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Completed 1 |
Follow Robert Redner, MD: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy mitoxantrone + etoposide + gemtuzumab ozogamicin - Acute Myeloid Leukemia | Phase 2 | Completed | Robert Redner, MD | 16 | 2019-02-28 | 2025-02-20 |
Etoposide (1) · Gemtuzumab (1) · Mitoxantrone (1)
United States (1)